000296013 001__ 296013
000296013 005__ 20250819094613.0
000296013 0247_ $$2doi$$a10.1080/2162402X.2024.2432726
000296013 0247_ $$2pmid$$apmid:39696783
000296013 0247_ $$2pmc$$apmc:PMC11660406
000296013 0247_ $$2ISSN$$a2162-4011
000296013 0247_ $$2ISSN$$a2162-402X
000296013 037__ $$aDKFZ-2024-02756
000296013 041__ $$aEnglish
000296013 082__ $$a610
000296013 1001_ $$aLaurent, Pierre-Antoine$$b0
000296013 245__ $$aPushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference.
000296013 260__ $$aAbingdon$$bTaylor & Franics$$c2025
000296013 3367_ $$2DRIVER$$aarticle
000296013 3367_ $$2DataCite$$aOutput Types/Journal article
000296013 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755589552_6400
000296013 3367_ $$2BibTeX$$aARTICLE
000296013 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296013 3367_ $$00$$2EndNote$$aJournal Article
000296013 520__ $$aOver the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer. Herein, we report on the topics developed by key-opinion leaders during the 7th Immunorad Conference held in Paris-Les Cordeliers (France) from September 27th to 29th 2023, and set the stage for the 8th edition of Immunorad which will be held at Weill Cornell Medical College (New-York, USA) in October 2024.
000296013 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000296013 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000296013 650_7 $$2Other$$aCancer
000296013 650_7 $$2Other$$aFLASH radiotherapy
000296013 650_7 $$2Other$$aT cells
000296013 650_7 $$2Other$$aimmune checkpoint
000296013 650_7 $$2Other$$aimmunorad
000296013 650_7 $$2Other$$aimmunotherapy
000296013 650_7 $$2Other$$alow-dose radiotherapy
000296013 650_7 $$2Other$$alymph-node sparing
000296013 650_7 $$2Other$$aradiotherapy
000296013 650_7 $$2Other$$atumor-associated macrophages
000296013 650_2 $$2MeSH$$aHumans
000296013 650_2 $$2MeSH$$aNeoplasms: immunology
000296013 650_2 $$2MeSH$$aNeoplasms: radiotherapy
000296013 650_2 $$2MeSH$$aNeoplasms: therapy
000296013 650_2 $$2MeSH$$aImmunotherapy: methods
000296013 650_2 $$2MeSH$$aCombined Modality Therapy
000296013 650_2 $$2MeSH$$aRadiotherapy: methods
000296013 7001_ $$aAndré, Fabrice$$b1
000296013 7001_ $$aBobard, Alexandre$$b2
000296013 7001_ $$aDeandreis, Desiree$$b3
000296013 7001_ $$aDemaria, Sandra$$b4
000296013 7001_ $$aDepil, Stephane$$b5
000296013 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b6$$udkfz
000296013 7001_ $$aFernandez-Palomo, Cristian$$b7
000296013 7001_ $$aFoijer, Floris$$b8
000296013 7001_ $$aGalluzzi, Lorenzo$$b9
000296013 7001_ $$aGalon, Jérôme$$b10
000296013 7001_ $$aGuckenberger, Matthias$$b11
000296013 7001_ $$aHarrington, Kevin J$$b12
000296013 7001_ $$aHerrera, Fernanda G$$b13
000296013 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter$$b14$$udkfz
000296013 7001_ $$aItaliano, Antoine$$b15
000296013 7001_ $$aKaram, Sana D$$b16
000296013 7001_ $$aKroemer, Guido$$b17
000296013 7001_ $$00000-0001-7961-0191$$aLambin, Philippe$$b18
000296013 7001_ $$aLeuschner, Carola$$b19
000296013 7001_ $$aMantovani, Alberto$$b20
000296013 7001_ $$aMeylan, Etienne$$b21
000296013 7001_ $$00000-0001-5803-0083$$aMondini, Michele$$b22
000296013 7001_ $$aPittet, Mikael J$$b23
000296013 7001_ $$aPouget, Jean-Pierre$$b24
000296013 7001_ $$aRemon, Jordi$$b25
000296013 7001_ $$aSørensen, Claus S$$b26
000296013 7001_ $$aSotiriou, Christos$$b27
000296013 7001_ $$aVanpouille-Box, Claire$$b28
000296013 7001_ $$aWeichselbaum, Ralph R$$b29
000296013 7001_ $$aWelsh, James W$$b30
000296013 7001_ $$aZitvogel, Laurence$$b31
000296013 7001_ $$aFormenti, Silvia C$$b32
000296013 7001_ $$00000-0002-8223-3697$$aDeutsch, Eric$$b33
000296013 773__ $$0PERI:(DE-600)2645309-5$$a10.1080/2162402X.2024.2432726$$gVol. 14, no. 1, p. 2432726$$n1$$p2432726$$tOncoImmunology$$v14$$x2162-4011$$y2025
000296013 909CO $$ooai:inrepo02.dkfz.de:296013$$pVDB
000296013 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000296013 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000296013 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000296013 9141_ $$y2025
000296013 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOIMMUNOLOGY : 2022$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-11-18T12:16:37Z
000296013 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-11-18T12:16:37Z
000296013 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-11-18T12:16:37Z
000296013 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOIMMUNOLOGY : 2022$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-19
000296013 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-19
000296013 9201_ $$0I:(DE-He78)D210-20160331$$kD210$$lGMP-Einheit Zelluläre Therapie$$x0
000296013 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000296013 980__ $$ajournal
000296013 980__ $$aVDB
000296013 980__ $$aI:(DE-He78)D210-20160331
000296013 980__ $$aI:(DE-He78)E055-20160331
000296013 980__ $$aUNRESTRICTED